Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECTRA Pilot: Ticagrelor Dose Reduction Post-MI
NCT03251859Phase 3Completed
- Sponsor
- Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ticagrelor in myocardial infarction (MI) (2 arms), sponsored by Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz. Primary endpoint: Platelet Reactivity Assessed with the VASP assay at 45 days. Started Aug 2017; status: completed.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03251859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251859.